Cargando…

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia

INTRODUCTION: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. METHODS: Newly diagnosed RUNX1-mutated AML...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nachmias, Boaz, Krichevsky, Svetlana, Filon, Dvora, Even-Or, Ehud, Gatt, Moshe E., Saban, Revital, Avni, Batia, Grisariu, Sigal, Aumann, Shlomzion, Vainstein, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808772/ https://www.ncbi.nlm.nih.gov/pubmed/35933982 http://dx.doi.org/10.1159/000526353

Ejemplares similares

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
por: Vainstein, Vladimir, et al.
Publicado: (2023)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
por: Morgenstern, Yael, et al.
Publicado: (2021)

Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
por: Sabbah, Rozan, et al.
Publicado: (2023)

Two decades of stem cell transplantation in patients with Fanconi anemia: Analysis of factors affecting transplant outcomes
por: Fink, Orly, et al.
Publicado: (2022)

Mesenchymal stroma/stem cells: Haematologists’ friend or foe?
por: Nachmias, Boaz, et al.
Publicado: (2022)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
por: Gross Even-Zohar, Noa, et al.
Publicado: (2022)

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
por: Asherie, Nathalie, et al.
Publicado: (2022)

P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
por: Lebel, Eyal, et al.
Publicado: (2023)

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Henig, Israel, et al.
Publicado: (2023)

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
por: Lebel, Eyal, et al.
Publicado: (2023)

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
por: Ram, Ron, et al.
Publicado: (2021)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
por: Asherie, N., et al.
Publicado: (2022)

Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Modulate Apoptosis, TNF Alpha and Interferon Gamma Response Gene mRNA Expression in T Lymphocytes
por: Fracchia, Andrea, et al.
Publicado: (2023)

Autoluminescent Plants
por: Krichevsky, Alexander, et al.
Publicado: (2010)

Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1
por: Lukes, Julius, et al.
Publicado: (2020)

Targeting nuclear import and export in hematological malignancies
por: Nachmias, Boaz, et al.
Publicado: (2020)

Src Kinase Phosphorylates RUNX3 at Tyrosine Residues and Localizes the Protein in the Cytoplasm
por: Goh, Yun-Mi, et al.
Publicado: (2010)

Runx1 Loss Minimally Impacts Long-Term Hematopoietic Stem Cells
por: Cai, Xiongwei, et al.
Publicado: (2011)

Star-Tracker Algorithm for Smartphones and Commercial Micro-Drones
por: Marbel, Revital, et al.
Publicado: (2020)

Diagnostic and Management Difficulty of Bleeding Aorto-Duodenal Fistula Associated with Hodgkin’s Lymphoma
por: Nachmias, Boaz, et al.
Publicado: (2021)

Runx Transcription Factors in T Cells—What Is Beyond Thymic Development?
por: Korinfskaya, Svetlana, et al.
Publicado: (2021)

Save Our Roads from GNSS Jamming: A Crowdsource Framework for Threat Evaluation
por: Yozevitch, Roi, et al.
Publicado: (2021)

Minimal residual disease in pediatric ALL
por: Pui, Ching-Hon, et al.
Publicado: (2017)

Minimal Residual Disease, Metastasis and Immunity
por: Badia-Ramentol, Jordi, et al.
Publicado: (2021)

Methods to detect minimal residual disease
por: Haferlach, Torsten
Publicado: (2018)

RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner
por: Abdallah, Mohamed Gaber, et al.
Publicado: (2021)

P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
por: Jentzsch, M., et al.
Publicado: (2022)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia
por: Sivagnanalingam, Umayal, et al.
Publicado: (2015)

Addiction to RUNX in lymphoma
por: Neil, James C., et al.
Publicado: (2016)

RUNX2 and Cancer
por: Lin, Tsung-Chieh
Publicado: (2023)

Thrombospondin-1 Is a Putative Target Gene of Runx2 and Runx3
por: Shi, Xiuming, et al.
Publicado: (2013)

The RUNX1/RUNX1T1 network: translating insights into therapeutic options
por: Swart, Laura E., et al.
Publicado: (2021)

On the way to specifically targeting minimal residual disease?
por: Gebauer, Gerhard
Publicado: (2008)

Assessment of Minimal Residual Disease in Ewing Sarcoma
por: Wagner, Lars M., et al.
Publicado: (2012)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5pt4svsvq4j303di0ornahomhv